ME1 Antibody
Description
Antibody Overview
ME1 antibodies exist in multiple formulations with distinct properties:
These antibodies enable ME1 detection in diverse experimental contexts, from basic protein localization studies to advanced functional analyses.
Target Biology
ME1 (UniProt ID: P48163) is a 572-amino acid cytosolic enzyme that catalyzes:
This reaction links glycolysis with the TCA cycle while supplying NADPH for lipid biosynthesis and oxidative stress mitigation .
Experimental Performance
-
Western Blot: Effective at dilutions up to 1:12,000 in liver tissue samples
-
Immunohistochemistry: Requires antigen retrieval with TE buffer (pH 9.0) for optimal results
-
Functional Studies: Gene silencing reduces NO production by 42% and ROS levels by 35% in LPS-activated macrophages
Cancer Biology
-
Breast Cancer: Elevated ME1 expression correlates with:
Immunometabolism
-
LPS-activated macrophages show:
-
ME1 knockdown decreases:
Clinical Significance
The monoclonal ME1 antibody (clone 99.1) demonstrates diagnostic utility:
| Tumor Type | ME1 Positivity Rate |
|---|---|
| Malignant Mesothelioma | 100% (40/40 cases) |
| Pulmonary Adenocarcinoma | 0% (0/19 cases) |
| Breast Adenocarcinoma | 10.5% (2/19 cases) |
This specificity enables differentiation between mesothelioma (strong diffuse staining) and adenocarcinomas (negative/weak focal staining) .
Product Specs
Target Background
The following studies highlight the functional roles and significance of ME1:
- Bioinformatics analysis revealed miR612 as a target of ME1, exhibiting high expression inversely correlated with miR612 expression in bladder cancer tissues. PMID: 29620192
- Malic enzyme 1 (ME1) has been identified as a viable target for molecular therapies in oral squamous cell carcinomas (OSCCs). PMID: 29601126
- Research indicates a direct interaction between ME1 and PPP, proposing an alternative model for signal transduction through protein conformational simulation and advancing understanding of metabolic pathway coordination in cancer. PMID: 28848047
- ME1/ME2 expression profiling may serve as a valuable marker for sebaceous differentiation in sebaceous lesions. PMID: 26381116
- ME1 expression demonstrated an association with mutant-KRAS in NSCLC cell lines. Patients with elevated ME1 exhibited poorer outcomes following radiotherapy, suggesting that ME1-mediated transamination and cytosolic NADPH generation may contribute to radioresistance. PMID: 26173780
- ME1 overexpression correlates with unfavorable prognoses in hepatocellular carcinoma (HCC) patients, indicating its potential as a poor prognostic indicator. PMID: 25753478
- ME1 plays a crucial role in cytosolic NADPH production and the maintenance of migratory and invasive capabilities of nasopharyngeal carcinoma cells. PMID: 23114090
- Studies have investigated the differential protein stability between dimer and tetramer interface interactions of human c-NADP-ME. PMID: 23284632
- p53 represses the expression of the tricarboxylic-acid-cycle-associated malic enzymes ME1 and ME2 in human and mouse cells. PMID: 23334421
- Cytosolic malic enzyme 1 gene polymorphism is associated with the degree of parathyroid hormone suppression following long-term calcium supplementation, potentially mediated by increased intestinal calcium absorption. PMID: 22456781
- ChIP-seq and knockdown analysis in HEK 293 cells identified ME1 as a functional target gene of the BACH1 transcription factor. PMID: 21555518
- A single Gln362 to Lys mutation in human m-NAD-ME converts it to an NADP+-dependent enzyme, characterized by its non-allosteric, non-cooperative, and NADP+-specific nature. PMID: 16757477
- While ME1 overexpression enhances anaplerosis and glucose-stimulated insulin secretion in INS-1 832/13 cells, its involvement in methyl succinate and glucose-stimulated insulin secretion in pancreatic islets is less clear. PMID: 19293334
- Human c-NADP-ME primarily exists as a tetramer, whereas human m-NAD(P)-ME exists as a mixture of dimers and tetramers. PMID: 19416979
- Analysis of R98/D102 mutants using double-mutant cycle analysis and kinetic studies revealed that the catalytic efficiency is significantly impacted by mutations in both Arg98 and Asp102 residues. PMID: 19464998
